No link between GLP-1 medicines and suicidal and self-injurious thoughts and actions
Several systems will be partially or fully inaccessible due to data transfers
The Data Analysis and Real World Interrogation Network seeks ten new data partners in 2024
New HTA regulation and clinical trials in the EU among key topics
How new ACT EU platform will enable collaboration on clinical research
Find medicine
What's new
FAQs
Latest news
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions
Due to planned system maintenance, several EMA applications will be fully or partially inaccessible from 11 to 17 April.
The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.
The European Medicines Agency's (EMA) office is closed from 18:30 on Wednesday 27 March 2024 to 07:30 on Tuesday 2 April 2024. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600.
EMA has issued recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2024.
Outcomes of the EMA Management Board meeting. The Management Board is an integral governance body of the Agency.
Information for you
Patients and carers
Healthcare professionals
Animal health professionals
Pharmaceutical Industry
Media
